Biotech companies are some of the riskiest in the market and may be getting riskier. That is one reason for the recent drought in big biotech deals.
So far this year, there have been four U.S. biotech acquisitions of publicly traded companies worth more than $100 million and none since May, according to Jefferies data. There were five last year and eight in 2016. While that is still fairly brisk activity by historical standards, many investors had expected a busier year.
...